doi	section	ITC num	Ind studies num	questions	decision	first	second	third	car_t_cells
10.1001/jamaophthalmol.2021.6284	methodology	1	NA	Treatment name 1	teprotumumab	Selective immunosuppressants	NA	NA	FALSE
10.1001/jamaophthalmol.2021.6284	methodology	1	NA	Treatment name 2	intravenous methylprednisolone	Glucocorticoids	NA	NA	FALSE
10.1002/edm2.259	methodology	1	NA	Treatment name 1	semaglutide 0.5  +  1 mg	Glucagon-like peptide-1 (GLP-1) analogues	NA	NA	FALSE
10.1002/edm2.259	methodology	1	NA	Treatment name 2	dulaglutide 1.5 mg	Glucagon-like peptide-1 (GLP-1) analogues	NA	NA	FALSE
10.1007/s00432-021-03602-w	methodology	1	NA	Treatment name 1	regorafenib	Other protein kinase inhibitors	NA	NA	FALSE
10.1007/s00432-021-03602-w	methodology	1	NA	Treatment name 2	cabozantinib	Other protein kinase inhibitors	NA	NA	FALSE
10.1007/s11523-021-00803-8	methodology	1	NA	Treatment name 1	lenvatinib	Other protein kinase inhibitors	NA	NA	FALSE
10.1007/s11523-021-00803-8	methodology	1	NA	Treatment name 2	atezolizumab + bevacizumab	Monoclonal antibodies	Monoclonal antibodies	NA	FALSE
10.1007/s12325-014-0167-z	methodology	1	NA	Treatment name 1	fingolimod	Selective immunosuppressants	NA	NA	FALSE
10.1007/s12325-014-0167-z	methodology	1	NA	Treatment name 2	dimethyl fumarate	Other immunosuppressants	NA	NA	FALSE
10.1007/s12325-014-0167-z	methodology	2	NA	Treatment name 1	fingolimod	Selective immunosuppressants	NA	NA	FALSE
10.1007/s12325-014-0167-z	methodology	2	NA	Treatment name 2	teriflunomide 7 mg	Selective immunosuppressants	NA	NA	FALSE
10.1007/s12325-014-0167-z	methodology	3	NA	Treatment name 1	fingolimod	Selective immunosuppressants	NA	NA	FALSE
10.1007/s12325-014-0167-z	methodology	3	NA	Treatment name 2	teriflunomide 14 mg	Selective immunosuppressants	NA	NA	FALSE
10.1007/s12325-018-0734-9	methodology	1	NA	Treatment name 1	dabrafenib + trametinib	B-raf serine-threonine kinase (BRAF) inhibitors	Mitogen-activated protein kinase (MEK) inhibitors	NA	FALSE
10.1007/s12325-018-0734-9	methodology	1	NA	Treatment name 2	nivolumab	Monoclonal antibodies	NA	NA	FALSE
10.1007/s12325-019-00991-w	methodology	1	NA	Treatment name 1	inotuzumab ozogamicin	Monoclonal antibodies	NA	NA	FALSE
10.1007/s12325-019-00991-w	methodology	1	NA	Treatment name 2	blinatumomab	Monoclonal antibodies	NA	NA	FALSE
10.1007/s12325-019-00991-w	methodology	2	NA	Treatment name 1	inotuzumab ozogamicin	Monoclonal antibodies	NA	NA	FALSE
10.1007/s12325-019-00991-w	methodology	2	NA	Treatment name 2	blinatumomab	Monoclonal antibodies	NA	NA	FALSE
10.1007/s12325-019-01157-4	methodology	1	NA	Treatment name 1	apalutamide	Anti-androgens	NA	NA	FALSE
10.1007/s12325-019-01157-4	methodology	1	NA	Treatment name 2	enzalutamide	Anti-androgens	NA	NA	FALSE
10.1007/s12325-019-01173-4	methodology	1	NA	Treatment name 1	ratiofrequency catheter ablation with ablation index	procedure	NA	NA	FALSE
10.1007/s12325-019-01173-4	methodology	1	NA	Treatment name 2	ratiofrequency catheter ablation with cryoballoon	procedure	NA	NA	FALSE
10.1007/s12325-020-01298-x	methodology	1	NA	Treatment name 1	intravitreally administered aflibercept (ivt-afl) with 2 weeks adjustment	Antineovascularisation agents	NA	NA	FALSE
10.1007/s12325-020-01298-x	methodology	1	NA	Treatment name 2	intravitreally administered aflibercept (ivt-afl) : one injection every 8 weeks in the first year followed by prorenata regimen in the second year	NA	NA	NA	NA
10.1007/s12325-021-01846-z	methodology	1	NA	Treatment name 1	thermocool smarttouch /thermocool smarttouch sf catheter with ai (stai)	NA	NA	NA	NA
10.1007/s12325-021-01846-z	methodology	1	NA	Treatment name 2	second-generation cryoballoon (cb)	procedure	NA	NA	FALSE
10.1007/s12325-021-01884-7	methodology	1	NA	Treatment name 1	belantamab mafodotin	Monoclonal antibodies	NA	NA	FALSE
10.1007/s12325-021-01884-7	methodology	1	NA	Treatment name 2	selinexor + dexamethasone	Other antineoplastic agents	Glucocorticoids	NA	FALSE
10.1007/s12325-022-02099-0	methodology	1	NA	Treatment name 1	transarterial radioembolization	NA	NA	NA	NA
10.1007/s12325-022-02099-0	methodology	1	NA	Treatment name 2	atezolizumab + bevacizumab	Monoclonal antibodies	Monoclonal antibodies	NA	FALSE
10.1007/s13555-021-00646-1	methodology	1	NA	Treatment name 1	crisaborole ointment 2%	Agents for dermatitis, excluding corticosteroids	NA	NA	FALSE
10.1007/s13555-021-00646-1	methodology	1	NA	Treatment name 2	pimecrolimus 1%	Agents for dermatitis, excluding corticosteroids	NA	NA	FALSE
10.1007/s13555-021-00646-1	methodology	2	NA	Treatment name 1	crisaborole	Agents for dermatitis, excluding corticosteroids	NA	NA	FALSE
10.1007/s13555-021-00646-1	methodology	2	NA	Treatment name 2	tacrolimus 0.03%	Agents for dermatitis, excluding corticosteroids	NA	NA	FALSE
10.1007/s13555-021-00646-1	methodology	3	NA	Treatment name 1	NA	NA	NA	NA	NA
10.1007/s13555-021-00646-1	methodology	3	NA	Treatment name 2	NA	NA	NA	NA	NA
10.1007/s40263-021-00805-0	methodology	1	NA	Treatment name 1	ozanimod	Selective immunosuppressants	NA	NA	FALSE
10.1007/s40263-021-00805-0	methodology	1	NA	Treatment name 2	dimethyl fumarate	Other immunosuppressants	NA	NA	FALSE
10.1007/s40273-021-01015-8	methodology	1	NA	Treatment name 1	lorlatinib	Anaplastic lymphoma kinase (ALK) inhibitors	NA	NA	FALSE
10.1007/s40273-021-01015-8	methodology	1	NA	Treatment name 2	pemetrexed or docetaxel	Folic acid analogues	Taxanes	NA	FALSE
10.1007/s40273-021-01015-8	methodology	2	NA	Treatment name 1	lorlatinib	Anaplastic lymphoma kinase (ALK) inhibitors	NA	NA	FALSE
10.1007/s40273-021-01015-8	methodology	2	NA	Treatment name 2	systemic therapy	supportive or standard of care	NA	NA	FALSE
10.1016/j.bbmt.2020.06.008	methodology	1	NA	Treatment name 1	axicabtagene ciloleucel	Other antineoplastic agents	NA	NA	TRUE
10.1016/j.bbmt.2020.06.008	methodology	1	NA	Treatment name 2	tisagenlecleucel	Other antineoplastic agents	NA	NA	FALSE
10.1016/j.bbmt.2020.06.008	methodology	2	NA	Treatment name 1	NA	NA	NA	NA	NA
10.1016/j.bbmt.2020.06.008	methodology	2	NA	Treatment name 2	NA	NA	NA	NA	NA
10.1016/j.clinthera.2015.09.013	methodology	1	NA	Treatment name 1	everolimus	Mammalian target of rapamycin (mTOR) kinase inhibitors	NA	NA	FALSE
10.1016/j.clinthera.2015.09.013	methodology	1	NA	Treatment name 2	axitinib	Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors	NA	NA	FALSE
10.1016/j.clinthera.2015.12.017	methodology	1	NA	Treatment name 1	daclatasvir + sofosbuvir	Antivirals for treatment of HCV infections	Antivirals for treatment of HCV infections	NA	FALSE
10.1016/j.clinthera.2015.12.017	methodology	1	NA	Treatment name 2	sofosbuvir + ribavirin	Antivirals for treatment of HCV infections	Antivirals for treatment of HCV infections	NA	FALSE
10.1016/j.clinthera.2017.08.010	methodology	1	NA	Treatment name 1	pomalidomide + dexamethasone	Other immunosuppressants	Glucocorticoids	NA	FALSE
10.1016/j.clinthera.2017.08.010	methodology	1	NA	Treatment name 2	daratumumab	Monoclonal antibodies	NA	NA	FALSE
10.1016/j.clinthera.2017.08.010	methodology	2	NA	Treatment name 1	pomalidomide + dexamethasone	Other immunosuppressants	Glucocorticoids	NA	FALSE
10.1016/j.clinthera.2017.08.010	methodology	2	NA	Treatment name 2	carfilzomib	Proteasome inhibitors	NA	NA	FALSE
10.1016/j.esmoop.2021.100050	methodology	1	NA	Treatment name 1	nivolumab + ipilimumab	Monoclonal antibodies	Monoclonal antibodies	NA	FALSE
10.1016/j.esmoop.2021.100050	methodology	1	NA	Treatment name 2	dabrafenib + trametinib	B-raf serine-threonine kinase (BRAF) inhibitors	Mitogen-activated protein kinase (MEK) inhibitors	NA	FALSE
10.1016/j.esmoop.2021.100050	methodology	2	NA	Treatment name 1	nivolumab + ipilimumab	Monoclonal antibodies	Monoclonal antibodies	NA	FALSE
10.1016/j.esmoop.2021.100050	methodology	2	NA	Treatment name 2	encorafenib + binimetinib	B-raf serine-threonine kinase (BRAF) inhibitors	Mitogen-activated protein kinase (MEK) inhibitors	NA	FALSE
10.1016/j.esmoop.2021.100050	methodology	3	NA	Treatment name 1	nivolumab + ipilimumab	Monoclonal antibodies	Monoclonal antibodies	NA	FALSE
10.1016/j.esmoop.2021.100050	methodology	3	NA	Treatment name 2	vemurafenib + cobimetinib	B-raf serine-threonine kinase (BRAF) inhibitors	Mitogen-activated protein kinase (MEK) inhibitors	NA	FALSE
10.1016/j.euo.2018.09.009	methodology	1	NA	Treatment name 1	pembrolizumab	Monoclonal antibodies	NA	NA	FALSE
10.1016/j.euo.2018.09.009	methodology	1	NA	Treatment name 2	carboplatin + gemcitabine	Platinum compounds	Pyrimidine analogues	NA	FALSE
10.1016/j.euo.2018.09.009	methodology	2	NA	Treatment name 1	pembrolizumab	Monoclonal antibodies	NA	NA	FALSE
10.1016/j.euo.2018.09.009	methodology	2	NA	Treatment name 2	gemcitabine	Pyrimidine analogues	NA	NA	FALSE
10.1016/j.jval.2018.03.015	methodology	1	NA	Treatment name 1	magnetic resonance-guided focused ultrasound	procedure	NA	NA	FALSE
10.1016/j.jval.2018.03.015	methodology	1	NA	Treatment name 2	unilateral deep brain stimulation	procedure	NA	NA	FALSE
10.1016/j.jval.2018.03.015	methodology	2	NA	Treatment name 1	magnetic resonance-guided focused ultrasound	procedure	NA	NA	FALSE
10.1016/j.jval.2018.03.015	methodology	2	NA	Treatment name 2	unilateral deep brain stimulation (dbs)	procedure	NA	NA	FALSE
10.1016/j.msard.2021.102972	methodology	1	NA	Treatment name 1	ozanimod	Selective immunosuppressants	NA	NA	FALSE
10.1016/j.msard.2021.102972	methodology	1	NA	Treatment name 2	teriflunomide	Selective immunosuppressants	NA	NA	FALSE
10.1080/03007995.2016.1248380	methodology	1	NA	Treatment name 1	dimethyl fumarate	Other immunosuppressants	NA	NA	FALSE
10.1080/03007995.2016.1248380	methodology	1	NA	Treatment name 2	fingolimod	Selective immunosuppressants	NA	NA	FALSE
10.1080/03007995.2018.1510225	methodology	1	NA	Treatment name 1	ponatinib	Bcr-abl tyrosine kinase inhibitors	NA	NA	FALSE
10.1080/03007995.2018.1510225	methodology	1	NA	Treatment name 2	bosutinib	Bcr-abl tyrosine kinase inhibitors	NA	NA	FALSE
10.1080/03007995.2018.1520696	methodology	1	NA	Treatment name 1	brigatinib	Anaplastic lymphoma kinase (ALK) inhibitors	NA	NA	FALSE
10.1080/03007995.2018.1520696	methodology	1	NA	Treatment name 2	ceritinib	Anaplastic lymphoma kinase (ALK) inhibitors	NA	NA	FALSE
10.1080/03007995.2018.1520696	methodology	2	NA	Treatment name 1	brigatinib	Anaplastic lymphoma kinase (ALK) inhibitors	NA	NA	FALSE
10.1080/03007995.2018.1520696	methodology	2	NA	Treatment name 2	ceritinib	Anaplastic lymphoma kinase (ALK) inhibitors	NA	NA	FALSE
10.1080/03007995.2018.1520696	methodology	3	NA	Treatment name 1	brigatinib	Anaplastic lymphoma kinase (ALK) inhibitors	NA	NA	FALSE
10.1080/03007995.2018.1520696	methodology	3	NA	Treatment name 2	alectinib	Anaplastic lymphoma kinase (ALK) inhibitors	NA	NA	FALSE
10.1080/03007995.2018.1520696	methodology	4	NA	Treatment name 1	brigatinib	Anaplastic lymphoma kinase (ALK) inhibitors	NA	NA	FALSE
10.1080/03007995.2018.1520696	methodology	4	NA	Treatment name 2	alectinib	Anaplastic lymphoma kinase (ALK) inhibitors	NA	NA	FALSE
10.1080/03007995.2019.1585779	methodology	1	NA	Treatment name 1	cladribine	Purine analogues	NA	NA	FALSE
10.1080/03007995.2019.1585779	methodology	1	NA	Treatment name 2	alemtuzumab	Selective immunosuppressants	NA	NA	FALSE
10.1080/03007995.2021.1896489	methodology	1	NA	Treatment name 1	bosutinib	Bcr-abl tyrosine kinase inhibitors	NA	NA	FALSE
10.1080/03007995.2021.1896489	methodology	1	NA	Treatment name 2	nilotinib	Bcr-abl tyrosine kinase inhibitors	NA	NA	FALSE
10.1080/03007995.2021.1896489	methodology	2	NA	Treatment name 1	bosutinib	Bcr-abl tyrosine kinase inhibitors	NA	NA	FALSE
10.1080/03007995.2021.1896489	methodology	2	NA	Treatment name 2	dasatinib	Bcr-abl tyrosine kinase inhibitors	NA	NA	FALSE
10.1185/03007995.2011.576238	methodology	1	NA	Treatment name 1	nilotinib	Bcr-abl tyrosine kinase inhibitors	NA	NA	FALSE
10.1185/03007995.2011.576238	methodology	1	NA	Treatment name 2	dasatinib	Bcr-abl tyrosine kinase inhibitors	NA	NA	FALSE
10.2165/11592490-000000000-00000	methodology	1	NA	Treatment name 1	vildagliptin 50 mg twice daily	Dipeptidyl peptidase 4 (DPP-4) inhibitors	NA	NA	FALSE
10.2165/11592490-000000000-00000	methodology	1	NA	Treatment name 2	sitagliptin 50 mg once daily	Dipeptidyl peptidase 4 (DPP-4) inhibitors	NA	NA	FALSE
10.2165/11592490-000000000-00000	methodology	2	NA	Treatment name 1	vildagliptin 50 mg twice daily	Dipeptidyl peptidase 4 (DPP-4) inhibitors	NA	NA	FALSE
10.2165/11592490-000000000-00000	methodology	2	NA	Treatment name 2	sitagliptin 50 mg once daily	Dipeptidyl peptidase 4 (DPP-4) inhibitors	NA	NA	FALSE
10.2165/11592490-000000000-00000	methodology	3	NA	Treatment name 1	vildagliptin 50 mg twice daily	Dipeptidyl peptidase 4 (DPP-4) inhibitors	NA	NA	FALSE
10.2165/11592490-000000000-00000	methodology	3	NA	Treatment name 2	sitagliptin 100 mg once daily	Dipeptidyl peptidase 4 (DPP-4) inhibitors	NA	NA	FALSE
10.1186/2162-3619-2-32	methodology	1	NA	Treatment name 1	everolimus	Mammalian target of rapamycin (mTOR) kinase inhibitors	NA	NA	FALSE
10.1186/2162-3619-2-32	methodology	1	NA	Treatment name 2	sunitinib	Other protein kinase inhibitors	NA	NA	FALSE
10.1186/2162-3619-2-32	methodology	2	NA	Treatment name 1	everolimus	Mammalian target of rapamycin (mTOR) kinase inhibitors	NA	NA	FALSE
10.1186/2162-3619-2-32	methodology	2	NA	Treatment name 2	placebo	placebo	NA	NA	FALSE
10.1186/2162-3619-2-32	methodology	3	NA	Treatment name 1	everolimus	Mammalian target of rapamycin (mTOR) kinase inhibitors	NA	NA	FALSE
10.1186/2162-3619-2-32	methodology	3	NA	Treatment name 2	sunitinib	Other protein kinase inhibitors	NA	NA	FALSE
10.2147/jbm.s104074	methodology	1	NA	Treatment name 1	bay 81-8973 (recombinant factor viii)	Blood coagulation factors	NA	NA	FALSE
10.2147/jbm.s104074	methodology	1	NA	Treatment name 2	rahf-pfm	Blood coagulation factors	NA	NA	FALSE
10.2147/jbm.s104074	methodology	2	NA	Treatment name 1	bay 81-8973 (recombinant factor viii)	Blood coagulation factors	NA	NA	FALSE
10.2147/jbm.s104074	methodology	2	NA	Treatment name 2	rahf-pfm	Blood coagulation factors	NA	NA	FALSE
10.2147/jbm.s104074	methodology	3	NA	Treatment name 1	bay 81-8973 (recombinant factor viii)	Blood coagulation factors	NA	NA	FALSE
10.2147/jbm.s104074	methodology	3	NA	Treatment name 2	turoctocog alfa	Blood coagulation factors	NA	NA	FALSE
10.2217/cer-2016-0085	methodology	1	NA	Treatment name 1	delayed-release dimethyl fumarate	Other immunosuppressants	NA	NA	FALSE
10.2217/cer-2016-0085	methodology	1	NA	Treatment name 2	glatiramer acetate	Other immunostimulants	NA	NA	FALSE
10.2217/cer-2016-0085	methodology	2	NA	Treatment name 1	delayed-release dimethyl fumarate	Other immunosuppressants	NA	NA	FALSE
10.2217/cer-2016-0085	methodology	2	NA	Treatment name 2	glatiramer acetate	Other immunostimulants	NA	NA	FALSE
10.2217/cer-2016-0085	methodology	3	NA	Treatment name 1	delayed-release dimethyl fumarate	Other immunosuppressants	NA	NA	FALSE
10.2217/cer-2016-0085	methodology	3	NA	Treatment name 2	glatiramer acetate	Other immunostimulants	NA	NA	FALSE
10.1155/2017/6121760	methodology	1	NA	Treatment name 1	sonidegib	Hedgehog pathway inhibitors	NA	NA	FALSE
10.1155/2017/6121760	methodology	1	NA	Treatment name 2	vismodegib	Hedgehog pathway inhibitors	NA	NA	FALSE
10.1634/theoncologist.2017-0103	methodology	1	NA	Treatment name 1	daratumumab	Monoclonal antibodies	NA	NA	FALSE
10.1634/theoncologist.2017-0103	methodology	1	NA	Treatment name 2	pomalidomide + low-dose dexamethasone	Other immunosuppressants	Glucocorticoids	NA	FALSE
10.1634/theoncologist.2017-0103	methodology	2	NA	Treatment name 1	daratumumab	Monoclonal antibodies	NA	NA	FALSE
10.1634/theoncologist.2017-0103	methodology	2	NA	Treatment name 2	pomalidomide + low-dose dexamethasone	Other immunosuppressants	Glucocorticoids	NA	FALSE
10.1097/brs.0000000000002647	methodology	1	NA	Treatment name 1	total disc replacement	NA	NA	NA	NA
10.1097/brs.0000000000002647	methodology	1	NA	Treatment name 2	fusion	NA	NA	NA	NA
10.1080/17474086.2018.1475226	methodology	1	NA	Treatment name 1	pembrolizumab	Monoclonal antibodies	NA	NA	FALSE
10.1080/17474086.2018.1475226	methodology	1	NA	Treatment name 2	st + ard of care	NA	supportive or standard of care	NA	FALSE
10.1186/s12885-018-5157-0	methodology	1	NA	Treatment name 1	axitinib	Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors	NA	NA	FALSE
10.1186/s12885-018-5157-0	methodology	1	NA	Treatment name 2	cabozantinib	Other protein kinase inhibitors	NA	NA	FALSE
10.1186/s12885-018-5157-0	methodology	2	NA	Treatment name 1	axitinib	Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors	NA	NA	FALSE
10.1186/s12885-018-5157-0	methodology	2	NA	Treatment name 2	everolimus	Mammalian target of rapamycin (mTOR) kinase inhibitors	NA	NA	FALSE
10.2147/ceor.s203482	methodology	1	NA	Treatment name 1	glasdegib + low-dose cytarabine	Hedgehog pathway inhibitors	Pyrimidine analogues	NA	FALSE
10.2147/ceor.s203482	methodology	1	NA	Treatment name 2	azacitidine	Pyrimidine analogues	NA	NA	FALSE
10.2147/ceor.s203482	methodology	2	NA	Treatment name 1	glasdegib + low-dose cytarabine	Hedgehog pathway inhibitors	Pyrimidine analogues	NA	FALSE
10.2147/ceor.s203482	methodology	2	NA	Treatment name 2	decitabine	Pyrimidine analogues	NA	NA	FALSE
10.1080/10428194.2019.1682571	methodology	1	NA	Treatment name 1	daratumumab–bortezomib–melphalan–prednisone	NA	NA	NA	NA
10.1080/10428194.2019.1682571	methodology	1	NA	Treatment name 2	lenalidomide–dexamethasone continuous	NA	NA	NA	NA
10.1080/10428194.2019.1682571	methodology	2	NA	Treatment name 1	daratumumab–bortezomib–melphalan–prednisone	NA	NA	NA	NA
10.1080/10428194.2019.1682571	methodology	2	NA	Treatment name 2	lenalidomide–dexamethasone 18 months (rd18)	NA	NA	NA	NA
10.1080/10428194.2019.1682571	methodology	3	NA	Treatment name 1	daratumumab–bortezomib–melphalan–prednisone	NA	NA	NA	NA
10.1080/10428194.2019.1682571	methodology	3	NA	Treatment name 2	melphalan–prednisone–thalidomide	NA	NA	NA	NA
10.1111/cea.13561	methodology	1	NA	Treatment name 1	benralizumab	Other systemic drugs for obstructive airway diseases	NA	NA	FALSE
10.1111/cea.13561	methodology	1	NA	Treatment name 2	mepolizumab	Other systemic drugs for obstructive airway diseases	NA	NA	FALSE
10.1111/cea.13561	methodology	2	NA	Treatment name 1	benralizumab	Other systemic drugs for obstructive airway diseases	NA	NA	FALSE
10.1111/cea.13561	methodology	2	NA	Treatment name 2	dupilumab	Agents for dermatitis, excluding corticosteroids	NA	NA	FALSE
10.1080/13696998.2020.1722139	methodology	1	NA	Treatment name 1	calcipotriene 0.005%/betamethasone dipropionate 0.064% foam	Other antipsoriatics for topical use	NA	NA	FALSE
10.1080/13696998.2020.1722139	methodology	1	NA	Treatment name 2	halobetasol 0.01%/tazarotene 0.045%	NA	NA	NA	NA
10.1136/rmdopen-2019-001131	methodology	1	NA	Treatment name 1	baricitinib	Selective immunosuppressants	NA	NA	FALSE
10.1136/rmdopen-2019-001131	methodology	1	NA	Treatment name 2	adalimumab	Tumor necrosis factor alpha (TNF-a) inhibitors	NA	NA	FALSE
10.1136/rmdopen-2019-001131	methodology	2	NA	Treatment name 1	baricitinib	Selective immunosuppressants	NA	NA	FALSE
10.1136/rmdopen-2019-001131	methodology	2	NA	Treatment name 2	tocilizumab	Interleukin inhibitors	NA	NA	FALSE
10.1136/rmdopen-2019-001131	methodology	3	NA	Treatment name 1	baricitinib	Selective immunosuppressants	NA	NA	FALSE
10.1136/rmdopen-2019-001131	methodology	3	NA	Treatment name 2	tofacitinib	Selective immunosuppressants	NA	NA	FALSE
10.2217/cer-2020-0063	methodology	1	NA	Treatment name 1	entrectinib	Other protein kinase inhibitors	NA	NA	FALSE
10.2217/cer-2020-0063	methodology	1	NA	Treatment name 2	crizotinib	Anaplastic lymphoma kinase (ALK) inhibitors	NA	NA	FALSE
10.2217/cer-2020-0063	methodology	2	NA	Treatment name 1	entrectinib	Other protein kinase inhibitors	NA	NA	FALSE
10.2217/cer-2020-0063	methodology	2	NA	Treatment name 2	pemetrexed + platinum followed by pemetrexed maintenance	Folic acid analogues	Platinum compounds	Folic acid analogues	FALSE
10.2217/cer-2020-0063	methodology	3	NA	Treatment name 1	entrectinib	Other protein kinase inhibitors	NA	NA	FALSE
10.2217/cer-2020-0063	methodology	3	NA	Treatment name 2	pemetrexed/docetaxel	Folic acid analogues	Taxanes	NA	FALSE
10.1080/14656566.2020.1811850	methodology	1	NA	Treatment name 1	patisiran	Other nervous system drugs	NA	NA	FALSE
10.1080/14656566.2020.1811850	methodology	1	NA	Treatment name 2	inotersen	Other nervous system drugs	NA	NA	FALSE
10.2217/cer-2020-0236	methodology	1	NA	Treatment name 1	nivolumab + ipilimumab	Monoclonal antibodies	Monoclonal antibodies	NA	FALSE
10.2217/cer-2020-0236	methodology	1	NA	Treatment name 2	placebo	placebo	NA	NA	FALSE
10.1097/ju.0000000000001767	methodology	1	NA	Treatment name 1	darolutamide	Anti-androgens	NA	NA	FALSE
10.1097/ju.0000000000001767	methodology	1	NA	Treatment name 2	apalutamide	Anti-androgens	NA	NA	FALSE
10.1097/ju.0000000000001767	methodology	2	NA	Treatment name 1	darolutamide	Anti-androgens	NA	NA	FALSE
10.1097/ju.0000000000001767	methodology	2	NA	Treatment name 2	enzalutamide	Anti-androgens	NA	NA	FALSE
10.1093/jnci/djab071	methodology	1	NA	Treatment name 1	abiraterone acetate	Other hormone antagonists and related agents	NA	NA	FALSE
10.1093/jnci/djab071	methodology	1	NA	Treatment name 2	placebo	placebo	NA	NA	FALSE
10.1080/10428194.2021.1913144	methodology	1	NA	Treatment name 1	acalabrutinib + obinutuzumab	Bruton's tyrosine kinase (BTK) inhibitors	Monoclonal antibodies	NA	FALSE
10.1080/10428194.2021.1913144	methodology	1	NA	Treatment name 2	ibrutinib	Bruton's tyrosine kinase (BTK) inhibitors	NA	NA	FALSE
10.1080/10428194.2021.1913144	methodology	2	NA	Treatment name 1	acalabrutinib	Bruton's tyrosine kinase (BTK) inhibitors	NA	NA	FALSE
10.1080/10428194.2021.1913144	methodology	2	NA	Treatment name 2	ibrutinib	Bruton's tyrosine kinase (BTK) inhibitors	NA	NA	FALSE
10.1080/10428194.2021.1913144	methodology	3	NA	Treatment name 1	acalabrutinib + obinutuzumab	Bruton's tyrosine kinase (BTK) inhibitors	Monoclonal antibodies	NA	FALSE
10.1080/10428194.2021.1913144	methodology	3	NA	Treatment name 2	ibrutinib + obinutuzumab	Bruton's tyrosine kinase (BTK) inhibitors	Monoclonal antibodies	NA	FALSE
10.1080/10428194.2021.1913144	methodology	4	NA	Treatment name 1	acalabrutinib	Bruton's tyrosine kinase (BTK) inhibitors	NA	NA	FALSE
10.1080/10428194.2021.1913144	methodology	4	NA	Treatment name 2	ibrutinib + obinutuzumab	Bruton's tyrosine kinase (BTK) inhibitors	Monoclonal antibodies	NA	FALSE
10.1080/10428194.2021.1913144	methodology	5	NA	Treatment name 1	acalabrutinib + obinutuzumab	Bruton's tyrosine kinase (BTK) inhibitors	Monoclonal antibodies	NA	FALSE
10.1080/10428194.2021.1913144	methodology	5	NA	Treatment name 2	venetoclax + obinutuzumab	Other antineoplastic agents	Monoclonal antibodies	NA	FALSE
10.1080/10428194.2021.1913144	methodology	6	NA	Treatment name 1	acalabrutinib	Bruton's tyrosine kinase (BTK) inhibitors	NA	NA	FALSE
10.1080/10428194.2021.1913144	methodology	6	NA	Treatment name 2	venetoclax + obinutuzumab	Other antineoplastic agents	Monoclonal antibodies	NA	FALSE
10.2147/jbm.s312885	methodology	1	NA	Treatment name 1	prior prophylaxis rfixfc	Blood coagulation factors	NA	NA	FALSE
10.2147/jbm.s312885	methodology	1	NA	Treatment name 2	prior prophylaxis rix-fp	Blood coagulation factors	NA	NA	FALSE
10.2147/jbm.s312885	methodology	2	NA	Treatment name 1	prior episodic treatment rfixfc	Blood coagulation factors	NA	NA	FALSE
10.2147/jbm.s312885	methodology	2	NA	Treatment name 2	prior episodic treatment rix-fp	Blood coagulation factors	NA	NA	FALSE
10.1080/03007995.2021.1971182	methodology	1	NA	Treatment name 1	pegcetacoplan	IMMUNOSUPPRESSANTS	NA	NA	FALSE
10.1080/03007995.2021.1971182	methodology	1	NA	Treatment name 2	ravulizumab	Selective immunosuppressants	NA	NA	FALSE
10.1080/14760584.2021.1994858	methodology	1	NA	Treatment name 1	15-valent pneumococcal conjugate vaccine	Pneumococcal vaccines	NA	NA	FALSE
10.1080/14760584.2021.1994858	methodology	1	NA	Treatment name 2	20-valent pneumococcal conjugate vaccine	Pneumococcal vaccines	NA	NA	FALSE
10.2147/jbm.s321288	methodology	1	NA	Treatment name 1	damoctocog alfa pegol (bay 94-9027)	Blood coagulation factors	NA	NA	FALSE
10.2147/jbm.s321288	methodology	1	NA	Treatment name 2	turoctocog alfa pegol (n8-gp)	Blood coagulation factors	NA	NA	FALSE
10.2147/ptt.s326121	methodology	1	NA	Treatment name 1	brodalumab	Interleukin inhibitors	NA	NA	FALSE
10.2147/ptt.s326121	methodology	1	NA	Treatment name 2	guselkumab	Interleukin inhibitors	NA	NA	FALSE
10.1210/clinem/dgab905	methodology	1	NA	Treatment name 1	semaglutide 2.0 mg	Glucagon-like peptide-1 (GLP-1) analogues	NA	NA	FALSE
10.1210/clinem/dgab905	methodology	1	NA	Treatment name 2	dulaglutide 3.0 mg	Glucagon-like peptide-1 (GLP-1) analogues	NA	NA	FALSE
10.1210/clinem/dgab905	methodology	2	NA	Treatment name 1	semaglutide 2.0 mg	Glucagon-like peptide-1 (GLP-1) analogues	NA	NA	FALSE
10.1210/clinem/dgab905	methodology	2	NA	Treatment name 2	dulaglutide 4.5 mg	Glucagon-like peptide-1 (GLP-1) analogues	NA	NA	FALSE
10.1186/s40164-022-00268-z	methodology	1	NA	Treatment name 1	lisocabtagene maraleucel	ANTINEOPLASTIC AGENTS	NA	NA	TRUE
10.1186/s40164-022-00268-z	methodology	1	NA	Treatment name 2	tisagenlecleucel	Other antineoplastic agents	NA	NA	FALSE
10.1111/j.1743-7563.2011.01400.x	methodology	1	NA	Treatment name 1	bevacizumab + cisplatin	Monoclonal antibodies	Platinum compounds	NA	FALSE
10.1111/j.1743-7563.2011.01400.x	methodology	1	NA	Treatment name 2	pemetrexed + cisplatin	Folic acid analogues	Platinum compounds	NA	FALSE
10.1007/bf03261873	methodology	1	NA	Treatment name 1	guanfacine extended-release low dose	Imidazoline receptor agonists	NA	NA	FALSE
10.1007/bf03261873	methodology	1	NA	Treatment name 2	atomoxetine	Centrally acting sympathomimetics	NA	NA	FALSE
10.1007/bf03261873	methodology	2	NA	Treatment name 1	guanfacine extended-release mid dose	Imidazoline receptor agonists	NA	NA	FALSE
10.1007/bf03261873	methodology	2	NA	Treatment name 2	atomoxetine	Centrally acting sympathomimetics	NA	NA	FALSE
10.1007/bf03261873	methodology	3	NA	Treatment name 1	guanfacine extended-release high dose	Imidazoline receptor agonists	NA	NA	FALSE
10.1007/bf03261873	methodology	3	NA	Treatment name 2	atomoxetine	Centrally acting sympathomimetics	NA	NA	FALSE
10.1007/s40263-013-0102-x	methodology	1	NA	Treatment name 1	guanfacine extended release	Imidazoline receptor agonists	NA	NA	FALSE
10.1007/s40263-013-0102-x	methodology	1	NA	Treatment name 2	atomoxetine	Centrally acting sympathomimetics	NA	NA	FALSE
10.1185/03007995.2014.977992	methodology	1	NA	Treatment name 1	nilotinib	Bcr-abl tyrosine kinase inhibitors	NA	NA	FALSE
10.1185/03007995.2014.977992	methodology	1	NA	Treatment name 2	dasatinib	Bcr-abl tyrosine kinase inhibitors	NA	NA	FALSE
10.2217/cer.15.33	methodology	1	NA	Treatment name 1	daclatasvir + asunaprevir	Antivirals for treatment of HCV infections	Antivirals for treatment of HCV infections	NA	FALSE
10.2217/cer.15.33	methodology	1	NA	Treatment name 2	telaprevir + peginterferon-Î± + ribavirin	Antivirals for treatment of HCV infections	Interferons	Antivirals for treatment of HCV infections	FALSE
10.2217/cer.15.33	methodology	2	NA	Treatment name 1	daclatasvir + asunaprevir	Antivirals for treatment of HCV infections	Antivirals for treatment of HCV infections	NA	FALSE
10.2217/cer.15.33	methodology	2	NA	Treatment name 2	boceprevir + peginterferon-Î± + ribavirin	Antivirals for treatment of HCV infections	Interferons	Antivirals for treatment of HCV infections	FALSE
10.2217/cer.15.33	methodology	3	NA	Treatment name 1	daclatasvir + asunaprevir	Antivirals for treatment of HCV infections	Antivirals for treatment of HCV infections	NA	FALSE
10.2217/cer.15.33	methodology	3	NA	Treatment name 2	simeprevir + peginterferon-Î± + ribavirin	Antivirals for treatment of HCV infections	Interferons	Antivirals for treatment of HCV infections	FALSE
10.2217/cer.15.33	methodology	4	NA	Treatment name 1	daclatasvir + asunaprevir	Antivirals for treatment of HCV infections	Antivirals for treatment of HCV infections	NA	FALSE
10.2217/cer.15.33	methodology	4	NA	Treatment name 2	sofosbuvir + peginterferon-Î± + ribavirin	Antivirals for treatment of HCV infections	Interferons	Antivirals for treatment of HCV infections	FALSE
10.2217/cer.15.33	methodology	5	NA	Treatment name 1	daclatasvir + asunaprevir	Antivirals for treatment of HCV infections	Antivirals for treatment of HCV infections	NA	FALSE
10.2217/cer.15.33	methodology	5	NA	Treatment name 2	peginterferon-Î± + ribavirin	Interferons	Antivirals for treatment of HCV infections	NA	FALSE
10.2217/cer.15.33	methodology	6	NA	Treatment name 1	daclatasvir + asunaprevir	Antivirals for treatment of HCV infections	Antivirals for treatment of HCV infections	NA	FALSE
10.2217/cer.15.33	methodology	6	NA	Treatment name 2	telaprevir + peginterferon-Î± + ribavirin	Antivirals for treatment of HCV infections	Interferons	Antivirals for treatment of HCV infections	FALSE
10.2217/cer.15.33	methodology	7	NA	Treatment name 1	daclatasvir + asunaprevir	Antivirals for treatment of HCV infections	Antivirals for treatment of HCV infections	NA	FALSE
10.2217/cer.15.33	methodology	7	NA	Treatment name 2	boceprevir + peginterferon-Î± + ribavirin	Antivirals for treatment of HCV infections	Interferons	Antivirals for treatment of HCV infections	FALSE
10.2217/cer.15.33	methodology	8	NA	Treatment name 1	daclatasvir + asunaprevir	Antivirals for treatment of HCV infections	Antivirals for treatment of HCV infections	NA	FALSE
10.2217/cer.15.33	methodology	8	NA	Treatment name 2	simeprevir + peginterferon-Î± + ribavirin	Antivirals for treatment of HCV infections	Interferons	Antivirals for treatment of HCV infections	FALSE
10.2217/cer.15.33	methodology	9	NA	Treatment name 1	daclatasvir + asunaprevir	Antivirals for treatment of HCV infections	Antivirals for treatment of HCV infections	NA	FALSE
10.2217/cer.15.33	methodology	9	NA	Treatment name 2	peginterferon-Î± + ribavirin	Interferons	Antivirals for treatment of HCV infections	NA	FALSE
10.1185/03007995.2015.1106934	methodology	1	NA	Treatment name 1	simeprevir + peginterferon alfa-2a + ribavirin	Antivirals for treatment of HCV infections	Interferons	Antivirals for treatment of HCV infections	FALSE
10.1185/03007995.2015.1106934	methodology	1	NA	Treatment name 2	peginterferon alfa-2a + ribavirin	Interferons	Antivirals for treatment of HCV infections	NA	FALSE
10.1185/03007995.2015.1106934	methodology	2	NA	Treatment name 1	simeprevir + peginterferon alfa-2a + ribavirin	Antivirals for treatment of HCV infections	Interferons	Antivirals for treatment of HCV infections	FALSE
10.1185/03007995.2015.1106934	methodology	2	NA	Treatment name 2	peginterferon alfa-2a + ribavirin	Interferons	Antivirals for treatment of HCV infections	NA	FALSE
10.1185/03007995.2015.1106934	methodology	3	NA	Treatment name 1	simeprevir + peginterferon alfa-2a + ribavirin	Antivirals for treatment of HCV infections	Interferons	Antivirals for treatment of HCV infections	FALSE
10.1185/03007995.2015.1106934	methodology	3	NA	Treatment name 2	peginterferon alfa-2a + ribavirin	Interferons	Antivirals for treatment of HCV infections	NA	FALSE
10.1185/03007995.2015.1106934	methodology	4	NA	Treatment name 1	simeprevir + peginterferon alfa-2a + ribavirin	Antivirals for treatment of HCV infections	Interferons	Antivirals for treatment of HCV infections	FALSE
10.1185/03007995.2015.1106934	methodology	4	NA	Treatment name 2	peginterferon alfa-2a + ribavirin	Interferons	Antivirals for treatment of HCV infections	NA	FALSE
10.1185/03007995.2015.1106934	methodology	5	NA	Treatment name 1	simeprevir + peginterferon alfa-2a + ribavirin	Antivirals for treatment of HCV infections	Interferons	Antivirals for treatment of HCV infections	FALSE
10.1185/03007995.2015.1106934	methodology	5	NA	Treatment name 2	peginterferon alfa-2a + ribavirin	Interferons	Antivirals for treatment of HCV infections	NA	FALSE
10.2217/cer.15.69	methodology	1	NA	Treatment name 1	daclatasvir + asunaprevir	Antivirals for treatment of HCV infections	Antivirals for treatment of HCV infections	NA	FALSE
10.2217/cer.15.69	methodology	1	NA	Treatment name 2	sofosbuvir + ledipasvir	Antivirals for treatment of HCV infections	Antivirals for treatment of HCV infections	NA	FALSE
10.1016/j.jtho.2016.05.029	methodology	1	NA	Treatment name 1	ceritinib	Anaplastic lymphoma kinase (ALK) inhibitors	NA	NA	FALSE
10.1016/j.jtho.2016.05.029	methodology	1	NA	Treatment name 2	crizotinib	Anaplastic lymphoma kinase (ALK) inhibitors	NA	NA	FALSE
10.1007/s40258-016-0271-0	methodology	1	NA	Treatment name 1	panobinostat + bortezomib + dexamethasone	Histone deacetylase (HDAC) inhibitors	Proteasome inhibitors	Glucocorticoids	FALSE
10.1007/s40258-016-0271-0	methodology	1	NA	Treatment name 2	lenalidomide + dexamethasone	Other immunosuppressants	Glucocorticoids	NA	FALSE
10.1186/s40734-017-0051-5	methodology	1	NA	Treatment name 1	deutetrabenazine	Other nervous system drugs	NA	NA	FALSE
10.1186/s40734-017-0051-5	methodology	1	NA	Treatment name 2	tetrabenazine	Other nervous system drugs	NA	NA	FALSE
10.1007/s12325-017-0564-1	methodology	1	NA	Treatment name 1	ibrutinib	Bruton's tyrosine kinase (BTK) inhibitors	NA	NA	FALSE
10.1007/s12325-017-0564-1	methodology	1	NA	Treatment name 2	obinutuzumab + chlorambucil	Monoclonal antibodies	Nitrogen mustard analogues	NA	FALSE
10.1007/s40744-017-0070-6	methodology	1	NA	Treatment name 1	adalimumab	Tumor necrosis factor alpha (TNF-a) inhibitors	NA	NA	FALSE
10.1007/s40744-017-0070-6	methodology	1	NA	Treatment name 2	secukinumab 150 mg	Interleukin inhibitors	NA	NA	FALSE
10.1007/s40744-017-0070-6	methodology	2	NA	Treatment name 1	adalimumab	Tumor necrosis factor alpha (TNF-a) inhibitors	NA	NA	FALSE
10.1007/s40744-017-0070-6	methodology	2	NA	Treatment name 2	secukinumab 300 mg	Interleukin inhibitors	NA	NA	FALSE
10.1080/13696998.2018.1443111	methodology	1	NA	Treatment name 1	ceritinib	Anaplastic lymphoma kinase (ALK) inhibitors	NA	NA	FALSE
10.1080/13696998.2018.1443111	methodology	1	NA	Treatment name 2	crizotinib	Anaplastic lymphoma kinase (ALK) inhibitors	NA	NA	FALSE
10.1007/s40744-018-0106-6	methodology	1	NA	Treatment name 1	secukinumab 150 mg	Interleukin inhibitors	NA	NA	FALSE
10.1007/s40744-018-0106-6	methodology	1	NA	Treatment name 2	adalimumab	Tumor necrosis factor alpha (TNF-a) inhibitors	NA	NA	FALSE
10.1007/s40744-018-0106-6	methodology	2	NA	Treatment name 1	secukinumab 300 mg	Interleukin inhibitors	NA	NA	FALSE
10.1007/s40744-018-0106-6	methodology	2	NA	Treatment name 2	adalimumab	Tumor necrosis factor alpha (TNF-a) inhibitors	NA	NA	FALSE
10.1007/s40744-018-0106-6	methodology	3	NA	Treatment name 1	secukinumab 150 mg	Interleukin inhibitors	NA	NA	FALSE
10.1007/s40744-018-0106-6	methodology	3	NA	Treatment name 2	adalimumab	Tumor necrosis factor alpha (TNF-a) inhibitors	NA	NA	FALSE
10.1007/s40744-018-0106-6	methodology	4	NA	Treatment name 1	secukinumab 300 mg	Interleukin inhibitors	NA	NA	FALSE
10.1007/s40744-018-0106-6	methodology	4	NA	Treatment name 2	adalimumab	Tumor necrosis factor alpha (TNF-a) inhibitors	NA	NA	FALSE
10.2147/cmar.s163478	methodology	1	NA	Treatment name 1	ribociclib	Cyclin-dependent kinase (CDK) inhibitors	NA	NA	FALSE
10.2147/cmar.s163478	methodology	1	NA	Treatment name 2	palbociclib	Cyclin-dependent kinase (CDK) inhibitors	NA	NA	FALSE
10.1093/europace/euy160	methodology	1	NA	Treatment name 1	rivaroxaban	Direct factor Xa inhibitors	NA	NA	FALSE
10.1093/europace/euy160	methodology	1	NA	Treatment name 2	rivaroxaban	Direct factor Xa inhibitors	NA	NA	FALSE
10.2217/cer-2018-0020	methodology	1	NA	Treatment name 1	sunitinib	Other protein kinase inhibitors	NA	NA	FALSE
10.2217/cer-2018-0020	methodology	1	NA	Treatment name 2	everolimus	Mammalian target of rapamycin (mTOR) kinase inhibitors	NA	NA	FALSE
10.2217/cer-2018-0020	methodology	2	NA	Treatment name 1	sunitinib	Other protein kinase inhibitors	NA	NA	FALSE
10.2217/cer-2018-0020	methodology	2	NA	Treatment name 2	everolimus	Mammalian target of rapamycin (mTOR) kinase inhibitors	NA	NA	FALSE
10.1183/13993003.01393-2018	methodology	1	NA	Treatment name 1	benralizumab	Other systemic drugs for obstructive airway diseases	NA	NA	FALSE
10.1183/13993003.01393-2018	methodology	1	NA	Treatment name 2	mepolizumab	Other systemic drugs for obstructive airway diseases	NA	NA	FALSE
10.1080/03007995.2018.1541443	methodology	1	NA	Treatment name 1	ceritinib	Anaplastic lymphoma kinase (ALK) inhibitors	NA	NA	FALSE
10.1080/03007995.2018.1541443	methodology	1	NA	Treatment name 2	crizotinib	Anaplastic lymphoma kinase (ALK) inhibitors	NA	NA	FALSE
10.1111/jdv.15369	methodology	1	NA	Treatment name 1	calcipotriol + betamethasone dipropionate aerosol foam	Other antipsoriatics for topical use	Corticosteroids, potent, other combinations	NA	FALSE
10.1111/jdv.15369	methodology	1	NA	Treatment name 2	apremilast	Selective immunosuppressants	NA	NA	FALSE
10.1111/jdv.15369	methodology	2	NA	Treatment name 1	calcipotriol + betamethasone dipropionate aerosol foam	Other antipsoriatics for topical use	Corticosteroids, potent, other combinations	NA	FALSE
10.1111/jdv.15369	methodology	2	NA	Treatment name 2	methotrexate	Folic acid analogues	NA	NA	FALSE
10.1111/jdv.15369	methodology	3	NA	Treatment name 1	calcipotriol + betamethasone dipropionate aerosol foam	Other antipsoriatics for topical use	Corticosteroids, potent, other combinations	NA	FALSE
10.1111/jdv.15369	methodology	3	NA	Treatment name 2	acitretin	Retinoids for treatment of psoriasis	NA	NA	FALSE
10.1111/jdv.15369	methodology	4	NA	Treatment name 1	calcipotriol + betamethasone dipropionate aerosol foam	Other antipsoriatics for topical use	Corticosteroids, potent, other combinations	NA	FALSE
10.1111/jdv.15369	methodology	4	NA	Treatment name 2	fumaric acid esters	Other antipsoriatics for systemic use	NA	NA	FALSE
10.1007/s12325-019-0873-7	methodology	1	NA	Treatment name 1	blinatumomab	Monoclonal antibodies	NA	NA	FALSE
10.1007/s12325-019-0873-7	methodology	1	NA	Treatment name 2	inotuzumab ozogamicin	Monoclonal antibodies	NA	NA	FALSE
10.1007/s12325-019-0873-7	methodology	2	NA	Treatment name 1	blinatumomab	Monoclonal antibodies	NA	NA	FALSE
10.1007/s12325-019-0873-7	methodology	2	NA	Treatment name 2	inotuzumab ozogamicin	Monoclonal antibodies	NA	NA	FALSE
10.2217/cer-2018-0141	methodology	1	NA	Treatment name 1	secukinumab 150mg	Interleukin inhibitors	NA	NA	FALSE
10.2217/cer-2018-0141	methodology	1	NA	Treatment name 2	infliximab	Tumor necrosis factor alpha (TNF-a) inhibitors	NA	NA	FALSE
10.2217/cer-2018-0141	methodology	2	NA	Treatment name 1	secukinumab 300mg	Interleukin inhibitors	NA	NA	FALSE
10.2217/cer-2018-0141	methodology	2	NA	Treatment name 2	infliximab	Tumor necrosis factor alpha (TNF-a) inhibitors	NA	NA	FALSE
10.1080/03007995.2019.1605239	methodology	1	NA	Treatment name 1	bosutinib	Bcr-abl tyrosine kinase inhibitors	NA	NA	FALSE
10.1080/03007995.2019.1605239	methodology	1	NA	Treatment name 2	dasatinib	Bcr-abl tyrosine kinase inhibitors	NA	NA	FALSE
10.1080/03007995.2019.1605239	methodology	2	NA	Treatment name 1	bosutinib	Bcr-abl tyrosine kinase inhibitors	NA	NA	FALSE
10.1080/03007995.2019.1605239	methodology	2	NA	Treatment name 2	nilotinib	Bcr-abl tyrosine kinase inhibitors	NA	NA	FALSE
10.5152/eurjrheum.2019.19057	methodology	1	NA	Treatment name 1	secukinumab 150 mg	Interleukin inhibitors	NA	NA	FALSE
10.5152/eurjrheum.2019.19057	methodology	1	NA	Treatment name 2	etanercept	Tumor necrosis factor alpha (TNF-a) inhibitors	NA	NA	FALSE
10.5152/eurjrheum.2019.19057	methodology	2	NA	Treatment name 1	secukinumab 150 mg	Interleukin inhibitors	NA	NA	FALSE
10.5152/eurjrheum.2019.19057	methodology	2	NA	Treatment name 2	etanercept	Tumor necrosis factor alpha (TNF-a) inhibitors	NA	NA	FALSE
10.5152/eurjrheum.2019.19057	methodology	3	NA	Treatment name 1	secukinumab 300mg	Interleukin inhibitors	NA	NA	FALSE
10.5152/eurjrheum.2019.19057	methodology	3	NA	Treatment name 2	etanercept	Tumor necrosis factor alpha (TNF-a) inhibitors	NA	NA	FALSE
10.5152/eurjrheum.2019.19057	methodology	4	NA	Treatment name 1	secukinumab 300mg	Interleukin inhibitors	NA	NA	FALSE
10.5152/eurjrheum.2019.19057	methodology	4	NA	Treatment name 2	etanercept	Tumor necrosis factor alpha (TNF-a) inhibitors	NA	NA	FALSE
10.2147/jbm.s206806	methodology	1	NA	Treatment name 1	bay 94-9027	Blood coagulation factors	NA	NA	FALSE
10.2147/jbm.s206806	methodology	1	NA	Treatment name 2	rfviiifc	Blood coagulation factors	NA	NA	FALSE
10.2147/jbm.s206806	methodology	2	NA	Treatment name 1	bay 94-9027	Blood coagulation factors	NA	NA	FALSE
10.2147/jbm.s206806	methodology	2	NA	Treatment name 2	bax 855	Blood coagulation factors	NA	NA	FALSE
10.2147/jbm.s206806	methodology	3	NA	Treatment name 1	bay 94-9027	Blood coagulation factors	NA	NA	FALSE
10.2147/jbm.s206806	methodology	3	NA	Treatment name 2	NA	NA	NA	NA	NA
10.2147/jbm.s206806	methodology	4	NA	Treatment name 1	bay 94-9027	Blood coagulation factors	NA	NA	FALSE
10.2147/jbm.s206806	methodology	4	NA	Treatment name 2	rahf-pfm 2012	Blood coagulation factors	NA	NA	FALSE
10.1007/s40263-019-00672-w	methodology	1	NA	Treatment name 1	brexanolone	PSYCHOANALEPTICS	NA	NA	FALSE
10.1007/s40263-019-00672-w	methodology	1	NA	Treatment name 2	placebo	placebo	NA	NA	FALSE
10.1080/10428194.2019.1675881	methodology	1	NA	Treatment name 1	vmp (bortezomib/melphalan/prednisone)	NA	Nitrogen mustard analogues	NA	FALSE
10.1080/10428194.2019.1675881	methodology	1	NA	Treatment name 2	modified vmp schedule	NA	NA	NA	NA
10.1016/j.clinthera.2019.09.012	methodology	1	NA	Treatment name 1	acalabrutinib	Bruton's tyrosine kinase (BTK) inhibitors	NA	NA	FALSE
10.1016/j.clinthera.2019.09.012	methodology	1	NA	Treatment name 2	ibrutinib	Bruton's tyrosine kinase (BTK) inhibitors	NA	NA	FALSE
10.1016/j.clinthera.2019.09.012	methodology	2	NA	Treatment name 1	acalabrutinib	Bruton's tyrosine kinase (BTK) inhibitors	NA	NA	FALSE
10.1016/j.clinthera.2019.09.012	methodology	2	NA	Treatment name 2	bortezomib	Proteasome inhibitors	NA	NA	FALSE
10.1016/j.clinthera.2019.09.012	methodology	3	NA	Treatment name 1	acalabrutinib	Bruton's tyrosine kinase (BTK) inhibitors	NA	NA	FALSE
10.1016/j.clinthera.2019.09.012	methodology	3	NA	Treatment name 2	lenalidomide	Other immunosuppressants	NA	NA	FALSE
10.1016/j.clinthera.2019.09.012	methodology	4	NA	Treatment name 1	acalabrutinib	Bruton's tyrosine kinase (BTK) inhibitors	NA	NA	FALSE
10.1016/j.clinthera.2019.09.012	methodology	4	NA	Treatment name 2	temsirolimus	Mammalian target of rapamycin (mTOR) kinase inhibitors	NA	NA	FALSE
10.1016/j.clinthera.2019.09.012	methodology	5	NA	Treatment name 1	acalabrutinib	Bruton's tyrosine kinase (BTK) inhibitors	NA	NA	FALSE
10.1016/j.clinthera.2019.09.012	methodology	5	NA	Treatment name 2	ibrutinib + rituximab	Bruton's tyrosine kinase (BTK) inhibitors	Monoclonal antibodies	NA	FALSE
10.1016/j.clinthera.2019.09.012	methodology	6	NA	Treatment name 1	acalabrutinib	Bruton's tyrosine kinase (BTK) inhibitors	NA	NA	FALSE
10.1016/j.clinthera.2019.09.012	methodology	6	NA	Treatment name 2	bendamustine + rituximab	Nitrogen mustard analogues	Monoclonal antibodies	NA	FALSE
10.1016/j.clinthera.2019.09.012	methodology	7	NA	Treatment name 1	acalabrutinib	Bruton's tyrosine kinase (BTK) inhibitors	NA	NA	FALSE
10.1016/j.clinthera.2019.09.012	methodology	7	NA	Treatment name 2	lenalidomide + rituximab	Other immunosuppressants	Monoclonal antibodies	NA	FALSE
10.1007/s12325-019-01156-5	methodology	1	NA	Treatment name 1	apalutamide	Anti-androgens	NA	NA	FALSE
10.1007/s12325-019-01156-5	methodology	1	NA	Treatment name 2	enzalutamide	Anti-androgens	NA	NA	FALSE
10.2217/cer-2019-0145	methodology	1	NA	Treatment name 1	nivolumab	Monoclonal antibodies	NA	NA	FALSE
10.2217/cer-2019-0145	methodology	1	NA	Treatment name 2	routine clinical practice	supportive or standard of care	NA	NA	FALSE
10.2217/cer-2019-0169	methodology	1	NA	Treatment name 1	ozanimod	Selective immunosuppressants	NA	NA	FALSE
10.2217/cer-2019-0169	methodology	1	NA	Treatment name 2	fingolimod	Selective immunosuppressants	NA	NA	FALSE
10.2217/cer-2019-0169	methodology	2	NA	Treatment name 1	ozanimod	Selective immunosuppressants	NA	NA	FALSE
10.2217/cer-2019-0169	methodology	2	NA	Treatment name 2	fingolimod	Selective immunosuppressants	NA	NA	FALSE
10.2217/cer-2019-0169	methodology	3	NA	Treatment name 1	ozanimod	Selective immunosuppressants	NA	NA	FALSE
10.2217/cer-2019-0169	methodology	3	NA	Treatment name 2	fingolimod	Selective immunosuppressants	NA	NA	FALSE
10.1080/03007995.2020.1747999	methodology	1	NA	Treatment name 1	siponimod	Selective immunosuppressants	NA	NA	FALSE
10.1080/03007995.2020.1747999	methodology	1	NA	Treatment name 2	ifnÎ²-1b 250 Î¼g once every other day (q2d)	Interferons	NA	NA	FALSE
10.1080/03007995.2020.1747999	methodology	2	NA	Treatment name 1	siponimod	Selective immunosuppressants	NA	NA	FALSE
10.1080/03007995.2020.1747999	methodology	2	NA	Treatment name 2	ifnÎ²-1a 22 Î¼g once weekly (qw)	Interferons	NA	NA	FALSE
10.1080/03007995.2020.1747999	methodology	3	NA	Treatment name 1	siponimod	Selective immunosuppressants	NA	NA	FALSE
10.1080/03007995.2020.1747999	methodology	3	NA	Treatment name 2	natalizumab	Selective immunosuppressants	NA	NA	FALSE
10.1080/03007995.2020.1747999	methodology	4	NA	Treatment name 1	siponimod	Selective immunosuppressants	NA	NA	FALSE
10.1080/03007995.2020.1747999	methodology	4	NA	Treatment name 2	sc ifnÎ²-1a 22 Î¼g three times weekly	Interferons	NA	NA	FALSE
10.1080/03007995.2020.1747999	methodology	5	NA	Treatment name 1	siponimod	Selective immunosuppressants	NA	NA	FALSE
10.1080/03007995.2020.1747999	methodology	5	NA	Treatment name 2	sc ifnÎ²-1a 44 Î¼g three times weekly	Interferons	NA	NA	FALSE
10.1080/03007995.2020.1747999	methodology	6	NA	Treatment name 1	siponimod	Selective immunosuppressants	NA	NA	FALSE
10.1080/03007995.2020.1747999	methodology	6	NA	Treatment name 2	ifnÎ²-1b 8 miu once every other day	Interferons	NA	NA	FALSE
10.1080/03007995.2020.1747999	methodology	7	NA	Treatment name 1	siponimod	Selective immunosuppressants	NA	NA	FALSE
10.1080/03007995.2020.1747999	methodology	7	NA	Treatment name 2	im ifnÎ²-1a 60 Î¼g once weekly	Interferons	NA	NA	FALSE
10.1080/09546634.2020.1747592	methodology	1	NA	Treatment name 1	ixekizumab	Interleukin inhibitors	NA	NA	FALSE
10.1080/09546634.2020.1747592	methodology	1	NA	Treatment name 2	guselkumab	Interleukin inhibitors	NA	NA	FALSE
10.1080/09546634.2020.1747592	methodology	2	NA	Treatment name 1	ixekizumab	Interleukin inhibitors	NA	NA	FALSE
10.1080/09546634.2020.1747592	methodology	2	NA	Treatment name 2	tildrakizumab 100mg	Interleukin inhibitors	NA	NA	FALSE
10.1080/09546634.2020.1747592	methodology	3	NA	Treatment name 1	ixekizumab	Interleukin inhibitors	NA	NA	FALSE
10.1080/09546634.2020.1747592	methodology	3	NA	Treatment name 2	tildrakizumab 200mg	Interleukin inhibitors	NA	NA	FALSE
10.1080/09546634.2020.1747592	methodology	4	NA	Treatment name 1	ixekizumab	Interleukin inhibitors	NA	NA	FALSE
10.1080/09546634.2020.1747592	methodology	4	NA	Treatment name 2	tildrakizumab 100mg	Interleukin inhibitors	NA	NA	FALSE
10.1080/09546634.2020.1747592	methodology	5	NA	Treatment name 1	ixekizumab	Interleukin inhibitors	NA	NA	FALSE
10.1080/09546634.2020.1747592	methodology	5	NA	Treatment name 2	tildrakizumab 200mg	Interleukin inhibitors	NA	NA	FALSE
10.1080/09546634.2020.1747592	methodology	6	NA	Treatment name 1	ixekizumab	Interleukin inhibitors	NA	NA	FALSE
10.1080/09546634.2020.1747592	methodology	6	NA	Treatment name 2	risankizumab	Interleukin inhibitors	NA	NA	FALSE
10.1080/09546634.2020.1747592	methodology	7	NA	Treatment name 1	ixekizumab	Interleukin inhibitors	NA	NA	FALSE
10.1080/09546634.2020.1747592	methodology	7	NA	Treatment name 2	risankizumab	Interleukin inhibitors	NA	NA	FALSE
10.1007/s12325-020-01378-y	methodology	1	NA	Treatment name 1	cabozantinib	Other protein kinase inhibitors	NA	NA	FALSE
10.1007/s12325-020-01378-y	methodology	1	NA	Treatment name 2	regorafenib	Other protein kinase inhibitors	NA	NA	FALSE
10.1007/s12325-020-01378-y	methodology	2	NA	Treatment name 1	NA	NA	NA	NA	NA
10.1007/s12325-020-01378-y	methodology	2	NA	Treatment name 2	NA	NA	NA	NA	NA
10.2217/cer-2020-0069	methodology	1	NA	Treatment name 1	tisagenlecleucel	Other antineoplastic agents	NA	NA	FALSE
10.2217/cer-2020-0069	methodology	1	NA	Treatment name 2	blinatumomab	Monoclonal antibodies	NA	NA	FALSE
10.2217/cer-2020-0069	methodology	2	NA	Treatment name 1	tisagenlecleucel	Other antineoplastic agents	NA	NA	FALSE
10.2217/cer-2020-0069	methodology	2	NA	Treatment name 2	clofarabine	Purine analogues	NA	NA	FALSE
10.2217/cer-2020-0069	methodology	3	NA	Treatment name 1	tisagenlecleucel	Other antineoplastic agents	NA	NA	FALSE
10.2217/cer-2020-0069	methodology	3	NA	Treatment name 2	clofarabine + etoposide plus cyclophosphamide	Purine analogues	NA	NA	FALSE
10.2217/cer-2020-0069	methodology	4	NA	Treatment name 1	tisagenlecleucel	Other antineoplastic agents	NA	NA	FALSE
10.2217/cer-2020-0069	methodology	4	NA	Treatment name 2	polychemotherapy/high-dose single-agent regimens/stem-cell transplantation (salvage-1)	NA	NA	NA	NA
10.2217/cer-2020-0069	methodology	5	NA	Treatment name 1	tisagenlecleucel	Other antineoplastic agents	NA	NA	FALSE
10.2217/cer-2020-0069	methodology	5	NA	Treatment name 2	palliative therapy/salvage therapy ± second stem-cell transplantation (salvage-2)	NA	NA	NA	NA
10.1016/j.clgc.2020.07.006	methodology	1	NA	Treatment name 1	pembrolizumab	Monoclonal antibodies	NA	NA	FALSE
10.1016/j.clgc.2020.07.006	methodology	1	NA	Treatment name 2	carboplatin + gemcitabine	Platinum compounds	Pyrimidine analogues	NA	FALSE
10.2217/fon-2020-0823	methodology	1	NA	Treatment name 1	cemiplimab	Monoclonal antibodies	NA	NA	FALSE
10.2217/fon-2020-0823	methodology	1	NA	Treatment name 2	erlotinib	Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors	NA	NA	FALSE
10.2217/fon-2020-0823	methodology	10	NA	Treatment name 1	cemiplimab	Monoclonal antibodies	NA	NA	FALSE
10.2217/fon-2020-0823	methodology	10	NA	Treatment name 2	gefitinib	Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors	NA	NA	FALSE
10.2217/fon-2020-0823	methodology	11	NA	Treatment name 1	cemiplimab	Monoclonal antibodies	NA	NA	FALSE
10.2217/fon-2020-0823	methodology	11	NA	Treatment name 2	dacomitinib	Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors	NA	NA	FALSE
10.2217/fon-2020-0823	methodology	12	NA	Treatment name 1	cemiplimab	Monoclonal antibodies	NA	NA	FALSE
10.2217/fon-2020-0823	methodology	12	NA	Treatment name 2	dacomitinib	Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors	NA	NA	FALSE
10.2217/fon-2020-0823	methodology	13	NA	Treatment name 1	cemiplimab	Monoclonal antibodies	NA	NA	FALSE
10.2217/fon-2020-0823	methodology	13	NA	Treatment name 2	panitumumab	Monoclonal antibodies	NA	NA	FALSE
10.2217/fon-2020-0823	methodology	14	NA	Treatment name 1	cemiplimab	Monoclonal antibodies	NA	NA	FALSE
10.2217/fon-2020-0823	methodology	14	NA	Treatment name 2	panitumumab	Monoclonal antibodies	NA	NA	FALSE
10.2217/fon-2020-0823	methodology	15	NA	Treatment name 1	cemiplimab	Monoclonal antibodies	NA	NA	FALSE
10.2217/fon-2020-0823	methodology	15	NA	Treatment name 2	pembrolizumab	Monoclonal antibodies	NA	NA	FALSE
10.2217/fon-2020-0823	methodology	16	NA	Treatment name 1	cemiplimab	Monoclonal antibodies	NA	NA	FALSE
10.2217/fon-2020-0823	methodology	16	NA	Treatment name 2	pembrolizumab	Monoclonal antibodies	NA	NA	FALSE
10.2217/fon-2020-0823	methodology	17	NA	Treatment name 1	cemiplimab	Monoclonal antibodies	NA	NA	FALSE
10.2217/fon-2020-0823	methodology	17	NA	Treatment name 2	pembrolizumab	Monoclonal antibodies	NA	NA	FALSE
10.2217/fon-2020-0823	methodology	18	NA	Treatment name 1	cemiplimab	Monoclonal antibodies	NA	NA	FALSE
10.2217/fon-2020-0823	methodology	18	NA	Treatment name 2	pembrolizumab	Monoclonal antibodies	NA	NA	FALSE
10.2217/fon-2020-0823	methodology	19	NA	Treatment name 1	cemiplimab	Monoclonal antibodies	NA	NA	FALSE
10.2217/fon-2020-0823	methodology	19	NA	Treatment name 2	cetuximab	Monoclonal antibodies	NA	NA	FALSE
10.2217/fon-2020-0823	methodology	2	NA	Treatment name 1	cemiplimab	Monoclonal antibodies	NA	NA	FALSE
10.2217/fon-2020-0823	methodology	2	NA	Treatment name 2	erlotinib	Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors	NA	NA	FALSE
10.2217/fon-2020-0823	methodology	20	NA	Treatment name 1	cemiplimab	Monoclonal antibodies	NA	NA	FALSE
10.2217/fon-2020-0823	methodology	20	NA	Treatment name 2	cetuximab	Monoclonal antibodies	NA	NA	FALSE
10.2217/fon-2020-0823	methodology	3	NA	Treatment name 1	cemiplimab	Monoclonal antibodies	NA	NA	FALSE
10.2217/fon-2020-0823	methodology	3	NA	Treatment name 2	platinum-based chemotherapy	Platinum compounds	NA	NA	FALSE
10.2217/fon-2020-0823	methodology	4	NA	Treatment name 1	cemiplimab	Monoclonal antibodies	NA	NA	FALSE
10.2217/fon-2020-0823	methodology	4	NA	Treatment name 2	platinum-based chemotherapy	Platinum compounds	NA	NA	FALSE
10.2217/fon-2020-0823	methodology	5	NA	Treatment name 1	cemiplimab	Monoclonal antibodies	NA	NA	FALSE
10.2217/fon-2020-0823	methodology	5	NA	Treatment name 2	cetuximab	Monoclonal antibodies	NA	NA	FALSE
10.2217/fon-2020-0823	methodology	6	NA	Treatment name 1	cemiplimab	Monoclonal antibodies	NA	NA	FALSE
10.2217/fon-2020-0823	methodology	6	NA	Treatment name 2	cetuximab	Monoclonal antibodies	NA	NA	FALSE
10.2217/fon-2020-0823	methodology	7	NA	Treatment name 1	cemiplimab	Monoclonal antibodies	NA	NA	FALSE
10.2217/fon-2020-0823	methodology	7	NA	Treatment name 2	cetuximab	Monoclonal antibodies	NA	NA	FALSE
10.2217/fon-2020-0823	methodology	8	NA	Treatment name 1	cemiplimab	Monoclonal antibodies	NA	NA	FALSE
10.2217/fon-2020-0823	methodology	8	NA	Treatment name 2	cetuximab	Monoclonal antibodies	NA	NA	FALSE
10.2217/fon-2020-0823	methodology	9	NA	Treatment name 1	cemiplimab	Monoclonal antibodies	NA	NA	FALSE
10.2217/fon-2020-0823	methodology	9	NA	Treatment name 2	gefitinib	Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors	NA	NA	FALSE
10.1007/s40744-020-00257-w	methodology	1	NA	Treatment name 1	upadacitinib monotherapy	Selective immunosuppressants	NA	NA	FALSE
10.1007/s40744-020-00257-w	methodology	1	NA	Treatment name 2	tofacitinib + methotrexate	Selective immunosuppressants	Folic acid analogues	NA	FALSE
10.1007/s40744-020-00257-w	methodology	2	NA	Treatment name 1	upadacitinib + methotrexate	Selective immunosuppressants	Folic acid analogues	NA	FALSE
10.1007/s40744-020-00257-w	methodology	2	NA	Treatment name 2	tofacitinib + methotrexate	Selective immunosuppressants	Folic acid analogues	NA	FALSE
10.1007/s12325-020-01599-1	methodology	1	NA	Treatment name 1	recombinant fviiifc	Blood coagulation factors	NA	NA	FALSE
10.1007/s12325-020-01599-1	methodology	1	NA	Treatment name 2	damoctocog alfa pegol (pooled prophylaxis)	Blood coagulation factors	NA	NA	FALSE
10.1007/s12325-020-01599-1	methodology	2	NA	Treatment name 1	recombinant fviiifc	Blood coagulation factors	NA	NA	FALSE
10.1007/s12325-020-01599-1	methodology	2	NA	Treatment name 2	damoctocog alfa pegol twice weekly	Blood coagulation factors	NA	NA	FALSE
10.1007/s12325-020-01599-1	methodology	3	NA	Treatment name 1	recombinant fviiifc	Blood coagulation factors	NA	NA	FALSE
10.1007/s12325-020-01599-1	methodology	3	NA	Treatment name 2	damoctocog alfa pegol q5d	Blood coagulation factors	NA	NA	FALSE
10.1007/s12325-020-01599-1	methodology	4	NA	Treatment name 1	recombinant fviiifc	Blood coagulation factors	NA	NA	FALSE
10.1007/s12325-020-01599-1	methodology	4	NA	Treatment name 2	damoctocog alfa pegol q7d	Blood coagulation factors	NA	NA	FALSE
10.1177/1756286420975916	methodology	1	NA	Treatment name 1	peginterferon beta-1a	Interferons	NA	NA	FALSE
10.1177/1756286420975916	methodology	1	NA	Treatment name 2	glatiramer acetate	Other immunostimulants	NA	NA	FALSE
10.2217/cer-2020-0272	methodology	1	NA	Treatment name 1	palbociclib + fulvestrant	Cyclin-dependent kinase (CDK) inhibitors	Anti-estrogens	NA	FALSE
10.2217/cer-2020-0272	methodology	1	NA	Treatment name 2	abemaciclib + fulvestrant	Cyclin-dependent kinase (CDK) inhibitors	Anti-estrogens	NA	FALSE
10.2217/cer-2020-0272	methodology	2	NA	Treatment name 1	palbociclib + fulvestrant	Cyclin-dependent kinase (CDK) inhibitors	Anti-estrogens	NA	FALSE
10.2217/cer-2020-0272	methodology	2	NA	Treatment name 2	ribociclib + fulvestrant	Cyclin-dependent kinase (CDK) inhibitors	Anti-estrogens	NA	FALSE
10.2147/jbm.s288283	methodology	1	NA	Treatment name 1	rfviiifc	Blood coagulation factors	NA	NA	FALSE
10.2147/jbm.s288283	methodology	1	NA	Treatment name 2	emicizumab every week	Other systemic hemostatics	NA	NA	FALSE
10.2147/jbm.s288283	methodology	2	NA	Treatment name 1	rfviiifc	Blood coagulation factors	NA	NA	FALSE
10.2147/jbm.s288283	methodology	2	NA	Treatment name 2	emicizumab every 2 weeks	Other systemic hemostatics	NA	NA	FALSE
10.2147/jbm.s288283	methodology	3	NA	Treatment name 1	rfviiifc	Blood coagulation factors	NA	NA	FALSE
10.2147/jbm.s288283	methodology	3	NA	Treatment name 2	emicizumab every 4 weeks	Other systemic hemostatics	NA	NA	FALSE
10.2217/cer-2020-0280	methodology	1	NA	Treatment name 1	glasdegib + low-dose cytarabine	Hedgehog pathway inhibitors	Pyrimidine analogues	NA	FALSE
10.2217/cer-2020-0280	methodology	1	NA	Treatment name 2	venetoclax + low-dose cytarabine	Other antineoplastic agents	Pyrimidine analogues	NA	FALSE
10.36469/jheor.2021.19008	methodology	1	NA	Treatment name 1	remestemcel-l-rknd	IMMUNOSUPPRESSANTS	NA	NA	FALSE
10.36469/jheor.2021.19008	methodology	1	NA	Treatment name 2	ruxolitinib	Janus-associated kinase (JAK) inhibitors	NA	NA	FALSE
10.1007/s12325-021-01700-2	methodology	1	NA	Treatment name 1	cabozantinib	Other protein kinase inhibitors	NA	NA	FALSE
10.1007/s12325-021-01700-2	methodology	1	NA	Treatment name 2	ramucirumab	Monoclonal antibodies	NA	NA	FALSE
10.1016/j.lungcan.2021.03.020	methodology	1	NA	Treatment name 1	pembrolizumab + chemotherapy	Monoclonal antibodies	ANTINEOPLASTIC AGENTS	NA	FALSE
10.1016/j.lungcan.2021.03.020	methodology	1	NA	Treatment name 2	atezolizumab + chemotherapy	Monoclonal antibodies	ANTINEOPLASTIC AGENTS	NA	FALSE
10.1016/j.lungcan.2021.03.020	methodology	2	NA	Treatment name 1	pembrolizumab + chemotherapy	Monoclonal antibodies	ANTINEOPLASTIC AGENTS	NA	FALSE
10.1016/j.lungcan.2021.03.020	methodology	2	NA	Treatment name 2	atezolizumab + bevacizumab + chemotherapy	Monoclonal antibodies	Monoclonal antibodies	ANTINEOPLASTIC AGENTS	FALSE
10.1080/10428194.2021.1913143	methodology	1	NA	Treatment name 1	idecabtagene vicleucel	ANTINEOPLASTIC AGENTS	NA	NA	TRUE
10.1080/10428194.2021.1913143	methodology	1	NA	Treatment name 2	selinexor + dexamethasone	Other antineoplastic agents	Glucocorticoids	NA	FALSE
10.1080/10428194.2021.1913143	methodology	2	NA	Treatment name 1	idecabtagene + vicleucel	ANTINEOPLASTIC AGENTS	ANTINEOPLASTIC AGENTS	NA	TRUE
10.1080/10428194.2021.1913143	methodology	2	NA	Treatment name 2	belantamab mafodotin	Monoclonal antibodies	NA	NA	FALSE
10.1007/s12325-021-01756-0	methodology	1	NA	Treatment name 1	lisocabtagene maraleucel	ANTINEOPLASTIC AGENTS	NA	NA	TRUE
10.1007/s12325-021-01756-0	methodology	1	NA	Treatment name 2	salvage chemotherapy	ANTINEOPLASTIC AGENTS	NA	NA	FALSE
10.1111/head.14128	methodology	1	NA	Treatment name 1	rimegepant	Calcitonin gene-related peptide (CGRP) antagonists	NA	NA	FALSE
10.1111/head.14128	methodology	1	NA	Treatment name 2	placebo	placebo	NA	NA	FALSE
10.1111/head.14128	methodology	2	NA	Treatment name 1	rimegepant	Calcitonin gene-related peptide (CGRP) antagonists	NA	NA	FALSE
10.1111/head.14128	methodology	2	NA	Treatment name 2	galcanezumab	Calcitonin gene-related peptide (CGRP) antagonists	NA	NA	FALSE
10.1111/head.14128	methodology	3	NA	Treatment name 1	rimegepant	Calcitonin gene-related peptide (CGRP) antagonists	NA	NA	FALSE
10.1111/head.14128	methodology	3	NA	Treatment name 2	placebo	placebo	NA	NA	FALSE
10.1111/head.14128	methodology	4	NA	Treatment name 1	rimegepant	Calcitonin gene-related peptide (CGRP) antagonists	NA	NA	FALSE
10.1111/head.14128	methodology	4	NA	Treatment name 2	erenumab	Calcitonin gene-related peptide (CGRP) antagonists	NA	NA	FALSE
10.3390/biom11060780	methodology	1	NA	Treatment name 1	gemcitabine + nab-paclitaxel	Pyrimidine analogues	Taxanes	NA	FALSE
10.3390/biom11060780	methodology	1	NA	Treatment name 2	folfirinox	ANTINEOPLASTIC AGENTS	NA	NA	FALSE
10.1080/03007995.2021.1947216	methodology	1	NA	Treatment name 1	onasemnogene abeparvovec	Other drugs for disorders of the musculo-skeletal system	NA	NA	FALSE
10.1080/03007995.2021.1947216	methodology	1	NA	Treatment name 2	nusinersen	Other drugs for disorders of the musculo-skeletal system	NA	NA	FALSE
10.1080/03007995.2021.1953456	methodology	1	NA	Treatment name 1	ciltacabtagene autoleucel	ANTINEOPLASTIC AGENTS	NA	NA	TRUE
10.1080/03007995.2021.1953456	methodology	1	NA	Treatment name 2	idecabtagene vicleucel	ANTINEOPLASTIC AGENTS	NA	NA	TRUE
10.1111/dom.14497	methodology	1	NA	Treatment name 1	semaglutide 1.0mg	Glucagon-like peptide-1 (GLP-1) analogues	NA	NA	FALSE
10.1111/dom.14497	methodology	1	NA	Treatment name 2	dulaglutide 3.0mg	Glucagon-like peptide-1 (GLP-1) analogues	NA	NA	FALSE
10.1111/dom.14497	methodology	2	NA	Treatment name 1	semaglutide 1.0mg	Glucagon-like peptide-1 (GLP-1) analogues	NA	NA	FALSE
10.1111/dom.14497	methodology	2	NA	Treatment name 2	dulaglutide 4.5mg	Glucagon-like peptide-1 (GLP-1) analogues	NA	NA	FALSE
10.1007/s12325-021-01853-0	methodology	1	NA	Treatment name 1	rviii-singlechain	Blood coagulation factors	NA	NA	FALSE
10.1007/s12325-021-01853-0	methodology	1	NA	Treatment name 2	rahf-pfm	Blood coagulation factors	NA	NA	FALSE
10.1007/s12325-021-01853-0	methodology	2	NA	Treatment name 1	rviii-singlechain	Blood coagulation factors	NA	NA	FALSE
10.1007/s12325-021-01853-0	methodology	2	NA	Treatment name 2	rahf-pfm	Blood coagulation factors	NA	NA	FALSE
10.1007/s12325-021-01853-0	methodology	3	NA	Treatment name 1	rviii-singlechain	Blood coagulation factors	NA	NA	FALSE
10.1007/s12325-021-01853-0	methodology	3	NA	Treatment name 2	rfviiifc	Blood coagulation factors	NA	NA	FALSE
10.1186/s13045-021-01144-9	methodology	1	NA	Treatment name 1	lisocabtagene maraleucel	ANTINEOPLASTIC AGENTS	NA	NA	TRUE
10.1186/s13045-021-01144-9	methodology	1	NA	Treatment name 2	axicabtagene ciloleucel	Other antineoplastic agents	NA	NA	TRUE
10.1177/17588359211049639	methodology	1	NA	Treatment name 1	olaparib + bevacizumab	Poly (ADP-ribose) polymerase (PARP) inhibitors	Monoclonal antibodies	NA	FALSE
10.1177/17588359211049639	methodology	1	NA	Treatment name 2	niraparib	Poly (ADP-ribose) polymerase (PARP) inhibitors	NA	NA	FALSE
10.1177/17588359211049639	methodology	2	NA	Treatment name 1	bevacizumab + placebo	Monoclonal antibodies	placebo	NA	FALSE
10.1177/17588359211049639	methodology	2	NA	Treatment name 2	niraparib	Poly (ADP-ribose) polymerase (PARP) inhibitors	NA	NA	FALSE
10.1177/17588359211049639	methodology	3	NA	Treatment name 1	olaparib + bevacizumab	Poly (ADP-ribose) polymerase (PARP) inhibitors	Monoclonal antibodies	NA	FALSE
10.1177/17588359211049639	methodology	3	NA	Treatment name 2	placebo	placebo	NA	NA	FALSE
10.1177/17588359211049639	methodology	4	NA	Treatment name 1	placebo + bevacizumab	placebo	Monoclonal antibodies	NA	FALSE
10.1177/17588359211049639	methodology	4	NA	Treatment name 2	placebo	placebo	NA	NA	FALSE
10.2217/cer-2021-0221	methodology	1	NA	Treatment name 1	palbociclib + fulvestrant	Cyclin-dependent kinase (CDK) inhibitors	Anti-estrogens	NA	FALSE
10.2217/cer-2021-0221	methodology	1	NA	Treatment name 2	abemaciclib + fulvestrant	Cyclin-dependent kinase (CDK) inhibitors	Anti-estrogens	NA	FALSE
10.2147/cmar.s325043	methodology	1	NA	Treatment name 1	ribociclib + fulvestrant	Cyclin-dependent kinase (CDK) inhibitors	Anti-estrogens	NA	FALSE
10.2147/cmar.s325043	methodology	1	NA	Treatment name 2	palbociclib + letrozole	Cyclin-dependent kinase (CDK) inhibitors	Aromatase inhibitors	NA	FALSE
10.2147/cmar.s325043	methodology	2	NA	Treatment name 1	placebo + fulvestrant	placebo	Anti-estrogens	NA	FALSE
10.2147/cmar.s325043	methodology	2	NA	Treatment name 2	letrozole	Aromatase inhibitors	NA	NA	FALSE
10.1007/s12325-021-01885-6	methodology	1	NA	Treatment name 1	apalutamide + adt	Anti-androgens	Anti-androgens	NA	FALSE
10.1007/s12325-021-01885-6	methodology	1	NA	Treatment name 2	darolutamide + adt	Anti-androgens	Anti-androgens	NA	FALSE
10.1016/j.ejcsup.2021.06.002	methodology	1	NA	Treatment name 1	[177lu]lu-dota-tate	Various therapeutic radiopharmaceuticals	NA	NA	FALSE
10.1016/j.ejcsup.2021.06.002	methodology	1	NA	Treatment name 2	everolimus	Mammalian target of rapamycin (mTOR) kinase inhibitors	NA	NA	FALSE
10.1016/j.ejcsup.2021.06.002	methodology	2	NA	Treatment name 1	[177lu]lu-dota-tate	Various therapeutic radiopharmaceuticals	NA	NA	FALSE
10.1016/j.ejcsup.2021.06.002	methodology	2	NA	Treatment name 2	best supportive care (bsc)	supportive or standard of care	NA	NA	FALSE
10.1016/j.ejcsup.2021.06.002	methodology	3	NA	Treatment name 1	[177lu]lu-dota-tate	Various therapeutic radiopharmaceuticals	NA	NA	FALSE
10.1016/j.ejcsup.2021.06.002	methodology	3	NA	Treatment name 2	sunitinib	Other protein kinase inhibitors	NA	NA	FALSE
10.1016/j.ejcsup.2021.06.002	methodology	4	NA	Treatment name 1	[177lu]lu-dota-tate	Various therapeutic radiopharmaceuticals	NA	NA	FALSE
10.1016/j.ejcsup.2021.06.002	methodology	4	NA	Treatment name 2	best supportive care	supportive or standard of care	NA	NA	FALSE
10.1016/j.ejcsup.2021.06.002	methodology	5	NA	Treatment name 1	[177lu]lu-dota-tate	Various therapeutic radiopharmaceuticals	NA	NA	FALSE
10.1016/j.ejcsup.2021.06.002	methodology	5	NA	Treatment name 2	everolimus	Mammalian target of rapamycin (mTOR) kinase inhibitors	NA	NA	FALSE
10.1016/j.ejcsup.2021.06.002	methodology	6	NA	Treatment name 1	[177lu]lu-dota-tate	Various therapeutic radiopharmaceuticals	NA	NA	FALSE
10.1016/j.ejcsup.2021.06.002	methodology	6	NA	Treatment name 2	best supportive care	supportive or standard of care	NA	NA	FALSE
10.1080/10428194.2021.2010069	methodology	1	NA	Treatment name 1	tisagenlecleucel	Other antineoplastic agents	NA	NA	FALSE
10.1080/10428194.2021.2010069	methodology	1	NA	Treatment name 2	lisocabtagene	ANTINEOPLASTIC AGENTS	NA	NA	TRUE
10.1080/03007995.2022.2030112	methodology	1	NA	Treatment name 1	amlodipine 5 mg + bisoprolol 5 mg	Dihydropyridine derivatives	Beta blocking agents, selective	NA	FALSE
10.1080/03007995.2022.2030112	methodology	1	NA	Treatment name 2	amlodipine 10mg,	Dihydropyridine derivatives	NA	NA	FALSE
10.2217/imt-2021-0273	methodology	1	NA	Treatment name 1	pembrolizumab	Monoclonal antibodies	NA	NA	FALSE
10.2217/imt-2021-0273	methodology	1	NA	Treatment name 2	nivolumab + ipilimumab	Monoclonal antibodies	Monoclonal antibodies	NA	FALSE
10.1007/s12325-022-02054-z	methodology	1	NA	Treatment name 1	tazemetostat	Other antineoplastic agents	NA	NA	FALSE
10.1007/s12325-022-02054-z	methodology	1	NA	Treatment name 2	idelalisib	Phosphatidylinositol-3-kinase (Pi3K) inhibitors	NA	NA	FALSE
10.1007/s12325-022-02054-z	methodology	2	NA	Treatment name 1	tazemetostat	Other antineoplastic agents	NA	NA	FALSE
10.1007/s12325-022-02054-z	methodology	2	NA	Treatment name 2	duvelisib	Phosphatidylinositol-3-kinase (Pi3K) inhibitors	NA	NA	FALSE
10.1007/s12325-022-02054-z	methodology	3	NA	Treatment name 1	tazemetostat	Other antineoplastic agents	NA	NA	FALSE
10.1007/s12325-022-02054-z	methodology	3	NA	Treatment name 2	copanlisib	Phosphatidylinositol-3-kinase (Pi3K) inhibitors	NA	NA	FALSE
10.1007/s12325-022-02054-z	methodology	4	NA	Treatment name 1	tazemetostat	Other antineoplastic agents	NA	NA	FALSE
10.1007/s12325-022-02054-z	methodology	4	NA	Treatment name 2	umbralisib	Other protein kinase inhibitors	NA	NA	FALSE
10.2217/fon-2021-1102	methodology	1	NA	Treatment name 1	crizotinib	Anaplastic lymphoma kinase (ALK) inhibitors	NA	NA	FALSE
10.2217/fon-2021-1102	methodology	1	NA	Treatment name 2	entrectinib	Other protein kinase inhibitors	NA	NA	FALSE
10.2217/fon-2021-1102	methodology	2	NA	Treatment name 1	crizotinib	Anaplastic lymphoma kinase (ALK) inhibitors	NA	NA	FALSE
10.2217/fon-2021-1102	methodology	2	NA	Treatment name 2	crizotinib	Anaplastic lymphoma kinase (ALK) inhibitors	NA	NA	FALSE
10.2217/fon-2021-1102	methodology	3	NA	Treatment name 1	crizotinib	Anaplastic lymphoma kinase (ALK) inhibitors	NA	NA	FALSE
10.2217/fon-2021-1102	methodology	3	NA	Treatment name 2	crizotinib	Anaplastic lymphoma kinase (ALK) inhibitors	NA	NA	FALSE
10.1080/10428194.2022.2047962	methodology	1	NA	Treatment name 1	carfizomib + dexamethasone+daratumumab	Proteasome inhibitors	Glucocorticoids	Monoclonal antibodies	FALSE
10.1080/10428194.2022.2047962	methodology	1	NA	Treatment name 2	daratumumab + velcade+dexamethasone	Monoclonal antibodies	Proteasome inhibitors	Glucocorticoids	FALSE
10.1111/bjd.16140	methodology	xx	NA	Treatment name 1	ixekizumab	Interleukin inhibitors	NA	NA	FALSE
10.1111/bjd.16140	methodology	xx	NA	Treatment name 2	secukinumab	Interleukin inhibitors	NA	NA	FALSE
10.1111/bjd.16140	methodology	xx	NA	Treatment name 1	ixekizumab	Interleukin inhibitors	NA	NA	FALSE
10.1111/bjd.16140	methodology	xx	NA	Treatment name 2	secukinumab	Interleukin inhibitors	NA	NA	FALSE
10.1111/bjd.16140	methodology	3	NA	Treatment name 1	ixekizumab	Interleukin inhibitors	NA	NA	FALSE
10.1111/bjd.16140	methodology	3	NA	Treatment name 2	secukinumab	Interleukin inhibitors	NA	NA	FALSE
10.1111/bjd.16140	methodology	xx	NA	Treatment name 1	ixekizumab	Interleukin inhibitors	NA	NA	FALSE
10.1111/bjd.16140	methodology	xx	NA	Treatment name 2	secukinumab	Interleukin inhibitors	NA	NA	FALSE
10.1111/bjd.16140	methodology	5	NA	Treatment name 1	ixekizumab	Interleukin inhibitors	NA	NA	FALSE
10.1111/bjd.16140	methodology	5	NA	Treatment name 2	secukinumab	Interleukin inhibitors	NA	NA	FALSE
10.1111/bjd.16140	methodology	xx	NA	Treatment name 1	ixekizumab	Interleukin inhibitors	NA	NA	FALSE
10.1111/bjd.16140	methodology	xx	NA	Treatment name 2	secukinumab	Interleukin inhibitors	NA	NA	FALSE
